Ultimovacs ASA: Share capital increase related to exercise of options
Oslo, 12 October 2021, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 5,850 through the issuance of 58,500 new shares, each with a par value of NOK 0.10. The resolution is based on an authorisation to increase the share capital granted by the Company's general meeting on 15 April 2021.
The new shares are issued to employees of the Company in connection with the Company's employee incentive program. 45,000 of the new shares are issued at a subscription price of NOK 31.25, and 13,500 shares at a subscription price of NOK 39.15.
Following registration of the share capital increase with the Norwegian Register of Business Enterprises, the Company will have a share capital of NOK 3,206,176.10, divided into 32,061,761 shares, each with a par value of NOK 0.10.
For further information, please contact:
Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA
Phone: +47 480 96 355
Carlos de Sousa, CEO
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Phone: +47 482 48632
Upcoming Life Sciences Events
- October 2021
- BIO-Europe® 2021
- Online: AusBiotech 2021 & Australia Biotech Invest & Partnering
- November 2021
- Pharma-Biotech Product & Company Valuation with Dr. P Frei
Latest company news
There are currently no news available for this portal